BIORIDIS Srl, Via Alfonso Rubbiani, 5, Bologna (BO) CAP 40124
presso TLS, Via Str. del Petriccio e Belriguardo, 35, 53100 Siena
Italia
BIORIDIS Srl
Cap. sociale 10.000€ i.v.
P.IVA 03514131204
QE-AMR
Quick and Easy AMR diagnosis
The World Health Organization has designated AntiMicrobial Resistance (AMR) as one of the highest priority health and social challenges and one of the top 10 global public health threats facing humanity.
More than 5,000,000 people die of drug-resistant infections every year, 10,000,000 by 2050
BIORIDIS responds to these important challenges and needs with its quick, reliable and easy to use QE-AMR assay. QE-AMR identifies antimicrobial resistant infections through detection of bacterial mRNA or small RNA. QE-AMR assay is based on our patented LIVELMIA technology and provided as a kit for quick and easy diagnosis. QE-AMR is a first in class technology.
The development was supported also by the EIT Health InnoStars Awards
#InnoStarsAwards2022, Final start-up https://lnkd.in/daSEyj_j, The Grand Final event: https://lnkd.in/dY_dBJpe
Decentralized Diagnosis
Improve AMR surveillance
Reduce misuse of antimicrobial
QE-AMR Platform
BIORIDIS, through its GEN-LIVELMIA software, can easily design and develop diagnostic kits specific for clinically relevant bacteria
Quick: Results in 1h
Easy: work directly on sample
High specificity and sensibility
QE-AMR Prototypes
Bioridis developed a series of prototypes for the detection of genes responsible for AMR to test and validate its platform.
*Priority developement for ESKAPE: 6 highly virulent and antibiotic resistant bacterial pathogens, 73% of deaths
